Supported by The American Heart Association(13SDG14640038);2012 Yale Center for Clinical Investigation cholar award to Santoro N;This publication was also made possible by CTSA Grant Number UL1 RR024139 from the National Center for Advancing Translational Science,a component of the National Institutes of Health(NIH),and NIH roadmap for Medical Research,Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH
Non-alcoholic fatty liver disease (NAFLD) comprehends a wide range of conditions, encompassing from fatty liver or steatohepatitis with or without fibrosis, to cirrhosis and its complications. NAFLD has become the mos...
This work was supposed by a grant from the Natural Science Foundation of Shandong Province, China (No. Y2005C45).
Background Primary liver cancer (PLC) is a common malignant tumor. Over the past decade, although farnesyltransferase (FTase) has emerged as a significant target for anticancer therapies and has become a hotspot o...
Two series of farnesyltransferase (FTase) inhibitors were grouped and their antimalarial activi-ties modeled by means of multivariate image analysis applied to quantitative structure-activity relationship (MIA-QSAR). ...
This work was supported by National Basic Research Program(973 Program:G1998051102).
S-akyl thiobenzoate compounds were designed as farnesyltransferase (FTase) inhibitors.An effective synthetic method was explored. The structures of the target compounds wereelucidated by NMR spectral and elemental ana...
A series of 3-methoxycarbonylpropoxy-7-(imidazol-4-ylpropinamide)-1, 3-dihydrogen- 1-methyl-5-phenyl-2H-1, 4-benzodiazepin-2-ones, as farnesyltransferase(Ftase) inhibitors, were synthesized. The preparation of the ke...
The 21-kDa Ras proteins are well known for their regulatory role in oncogenic, mitogenic, and developmental signaling pathways. GTP activated Ras interacts directly with the Raf protein to recruit the MAP kinases and ...